Vimarsana
Biggest News Aggregation in the World

Roberto Diletti News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Roberto Diletti. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Roberto Diletti Today - Breaking & Trending Today

Immediate complete revascularization is not inferior to staged procedure for treating multi-vessel disease - Vimarsana News

Immediate complete revascularization is not inferior to staged procedure for treating multi-vessel disease

In patients with multi-vessel heart disease who have had a heart attack, immediate treatment with stents in all diseased arteries was found to be as safe and effective at one year of follow-up as staged treatment, according to findings from the first large, randomized trial to address this question that is being presented at the American College of Cardiology's Annual Scientific Session Together With the World Congress of Cardiology. In staged treatment, the blocked artery that caused the heart attack is treated with a stent immediately and other partially blocked arteries are treated in a...

No Downside to Immediate Complete Revascularization in ACS: BIOVASC - Vimarsana News

No Downside to Immediate Complete Revascularization in ACS: BIOVASC

There was a higher rate of MI in the staged group, which might reflect operators misjudging the culprit lesion.

Source: tctmd.com
Immediate Complete Revascularization as Safe and Effective as Staged Procedure in Treating Multi-Vessel Disease - Vimarsana News

Immediate Complete Revascularization as Safe and Effective as Staged Procedure in Treating Multi-Vessel Disease

Approach may prevent second heart attacks compared to staged approach

BIOVASC: Immediate Complete Revascularization Beneficial in ACS - Vimarsana News

BIOVASC: Immediate Complete Revascularization Beneficial in ACS

Immediate complete revascularization during the index procedure might become the new treatment paradigm in patients with ACS and multivessel disease, results of the BIOVASC trial suggest.